Navigation Links
Joint preservation in osteoarthritis

Reconstructive surgical approaches can help delay endoprosthetic joint replacement in patients with osteoarthritis. Henning Madry and coauthors introduce such procedures in the current issue of Deutsches rzteblatt International (Dtsch Arztebl Int 2011; 108[40]: 669-77).

Articular cartilage defects often develop subsequent to injury or osteoarthritis. The authors in their article provide an overview of currently available medical and surgical therapeutic options. Medical therapy aims to preserve articular function for as long as possible and to delay surgical intervention. Further to the primarily pain-relieving symptomatic medication, causal treatment with glucosamine and chondroitin aims to improve the joint itself. However, no medical drugs are currently available that can slow down or reverse the process of cartilage degeneration. Surgical measures aim to trigger formation of repair tissue or partially relieve the weight placed on the joint. These procedures include debridement of cartilaginous fragments, marrow-stimulating techniques, transplantation of cartilaginous cells or stem cells, and weight relief by means of osteotomy.


Contact: Dr. Henning Madry
Deutsches Aerzteblatt International

Page: 1

Related medicine news :

1. More African-Americans burdened by osteoarthritis in multiple large joints
2. FDA and NIH announce joint study on tobacco use and risk perceptions
3. Radiation boost for artificial joints
4. Lawson scientist presents joint pain treatment 2.0
5. Vitamin D relieves joint, muscle pain for breast cancer patients
6. Joint winners announced in Research4life global case study competition
7. Men Who Smoke at Lower Risk of Joint Replacement: Study
8. Male smokers less likely to need joint replacement surgery of hip or knee
9. Those aching joints could be in your genes
10. UNH launches joint Sustainable Agro-Ecosystems Lab with Chinese Academy
11. Joint Replacement Risks Rise at Less Experienced Hospitals
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: